An investigation into the $368 billion AI healthcare revolution — and the visionary CEO determined to make cancer a preventable disease.
The $368 billion cancer diagnostics market is no longer just about tests—it’s about rewriting the future of human health. At the center of this shift is SooYoun Chang, the Prevenotics CEO turning personal tragedy into a mission to end cancer.
The trillion-dollar transformation: When prevention meets precision
The global healthcare industry stands at an inflection point that will define the next century of human health. The cancer diagnostics market, reaching $240 billion in 2023 and projected to hit $368.1 billion by 2030, represents more than just numbers—it’s the economic architecture of a fundamental shift from reactive treatment to predictive prevention. At the center of this transformation stands Prevenotics CEO SooYoun Chang, whose journey from personal tragedy to technological triumph embodies the convergence of artificial intelligence and healthcare that promises nothing less than the end of cancer as we know it.
The mathematics are staggering and undeniable. McKinsey & Company’s latest healthcare digitization analysis reveals that AI-powered early detection could slash global healthcare costs by $100 billion annually by 2030. Yet this figure barely captures the true magnitude of what’s emerging: a complete reimagining of how humanity confronts its most feared disease.
The Korean advantage: A blueprint for global cancer elimination
Chang’s mission crystallized from watching her physician father miss crucial early intervention opportunities despite his medical expertise. The statistics that emerged from this personal loss reveal a staggering market failure: Korea achieves 78 percent five-year survival rates for gastric cancer compared to just 25 percent in the United States.
“This isn’t about medical capability; it’s about systematic early detection protocols,” Chang reflects. When gastric cancer is caught at stage one, survival rates soar to 96 percent. At stage four, they plummet to 7 percent.
The Prevenotics Max Pro, with over 90 percent accuracy in under three minutes, essentially democratizes Korea’s early detection excellence through AI—transforming specialized medical expertise into scalable, accessible technology
The convergence imperative: AI, genetics, and the multi-modal future
The most compelling aspect of Prevenotics’ trajectory isn’t its current capability, but its positioning within the broader AI-healthcare convergence. Industry leaders such as Guardant Health, Grail, and Exact Sciences should not be viewed as competitors but as complementary partners in an emerging ecosystem. While their platforms rely on liquid biopsy or stool DNA tests, the integration of these genetic-based modalities with Prevenotics’ endoscopic AI solution could create a near-100% precision pathway—detecting both pre-cancerous conditions and early-stage cancers.
This multi-modal approach represents the future of cancer elimination: AI-powered imaging combined with genetic analysis, creating detection systems so comprehensive that cancer becomes a preventable disease rather than a treatment challenge. The convergence suggests that the long-held aspiration of a cancer-free future may become a realistic possibility when these technologies are strategically combined.
System-wide cost savings vs. market revenue opportunity
The market dynamics reveal profound structural inefficiencies ripe for disruption. McKinsey & Company’s latest analysis shows AI-powered early detection is poised to unlock up to $100 billion in annual healthcare cost savings by 2030, a figure that represents the beginning of a system-wide transformation.
This cost differential becomes clear when examining treatment economics: early-stage treatment costs range from $15,000-$50,000 per patient, while advanced-stage treatment exceeds $200,000. With current market penetration representing less than 15% of optimal early detection capacity, this creates a $40-70 billion annual addressable market opportunity for companies developing prevention-focused healthcare solutions.
The investment momentum supports this transformation, with The investment momentum supports this transformation, with analyses showing tens of billions flowing into digital health solutions, with AI diagnostics capturing the largest share of this capital in 2023. The World Economic Forum projects this acceleration continuing through Fourth Industrial Revolution technologies, even as WHO’s sobering cancer incidence projections show a dramatic increase by 2040, making this transformation not just opportunistic, but existentially necessary.
Beyond detection: The network effects of trust and technology
Chang’s expansion from gastric to esophageal and colorectal cancers through the Prevenotics Max Pro demonstrates understanding that successful healthcare AI requires both technical accuracy and cultural fluency. Her team’s composition—combining Seoul National University Hospital medical expertise, former LG Electronics AI development talent, now at Prevenotics, and pharmaceutical business acumen—reflects sophisticated understanding of the “trust chasm” that prevents optimal healthcare technology adoption.
“Our goal isn’t just Korean market domination,” Chang emphasizes. “We’re building a comprehensive cancer prevention ecosystem that can scale globally. Each successful deployment creates network effects—physicians see results, trust builds, adoption accelerates.” This strategic insight parallels successful cross-border expansion models where relationship-first marketing creates sustainable competitive advantages.
The fourth industrial revolution meets healthcare’s greatest challenge
The convergence of AI and healthcare represents more than technological advancement—it’s the emergence of what could be termed “predictive medicine.” World Economic Forum projections position this transformation at the intersection of three megatrends: AI democratization of medical expertise, healthcare cost containment pressure, and preventive care infrastructure development. WHO cancer incidence projections showing 70 percent increase by 2040 make this transformation not just opportunistic but existentially necessary.
Prevenotics’ 2025 CES Innovation Award win underscored its positioning not just as a technology vendor but as a category authority—building the trust infrastructure necessary for healthcare system transformation. By positioning Prevenotics as category authority rather than mere technology vendor, the company builds the trust infrastructure necessary for healthcare system transformation.
The economics of elimination: ROI in human terms
The economic logic remains irrefutable: early detection represents the highest ROI healthcare intervention available, yet remains systematically underdelivered. McKinsey’s analysis reveals a “3:1 to 7:1 ROI opportunity” for early intervention programs—economics that companies like Prevenotics are uniquely positioned to capture. The World Economic Forum’s Global Health Security Index exposes critical gaps in early detection capabilities, with preventive care infrastructure lagging decades behind treatment-focused models.
This structural misalignment creates what could be the largest arbitrage opportunity in healthcare history. The $275-460 million lifetime market opportunities in targeted segments represent just the beginning of a prevention economy that could fundamentally restructure healthcare’s trillion-dollar ecosystem.
The vision: From personal mission to species-level impact
As healthcare systems globally confront unsustainable cost trajectories and aging demographics, the question isn’t whether AI-powered early detection will dominate, but which companies will establish market-leading positions before this transition accelerates. Prevenotics, with its proven technology platform and strategic expansion vision, appears uniquely positioned to lead this transformation—converting personal mission into global healthcare revolution while building substantial commercial value.
The convergence of AI and healthcare, exemplified by Prevenotics’ evolution from the G Pro to Max Pro, represents more than incremental improvement—it’s the engineering of humanity’s victory over cancer. When detection becomes prediction, treatment becomes prevention, and suffering becomes optional, we witness not just technological advancement but the dawn of post-cancer civilization.
The economic imperatives are clear, the technology is proven, and the leadership is in place. The only question remaining is how quickly humanity will embrace the end of cancer as we’ve known it—and begin the era of cancer as a preventable footnote in medical history.
David Kim, a former investment banker and CEO, is now a tech journalist and growth strategist focusing on Asia’s digital transformation and innovation ecosystems.
TNGlobal INSIDER publishes contributions relevant to entrepreneurship and innovation. You may submit your own original or published contributions subject to editorial discretion.
Featured image: MW on Unsplash
Vietnam’s scaling challenge: Why the next tech boom needs strategic leaders, not just smart capital